Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The JAK1/2 inhibitor baricitinib revealed unique immune biomarkers in multirefractory immune thrombocytopenia patients

View Full Paper
Ask AI
Bookmark
Share

Authors

HFHaixia Fu

Discussion

Loading...

Member takes

Overview

Immune dysregulation alters immune profiles in multirefractory thrombocytopenia, indicating baricitinib may restore balance.

Key Points

  • High-dimensional mass cytometry identifies immune dysregulation in multirefractory immune thrombocytopenia patients.
  • Myeloid-derived suppressor cells were reduced by 70% in multirefractory patients compared to controls.
  • Statistical modeling revealed changes in natural killer cell populations following baricitinib treatment.
  • Corticosteroids are inadequate in managing dual-treatment resistant immune thrombocytopenia.

Cite This Study

Haixia Fu (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e116https://doi.org/10.1182/blood-2025-4820
View Full Paper
Ask AI
Bookmark
Share